Aspira Women's Health Inc. (AWH)

NASDAQ: AWH · IEX Real-Time Price · USD
4.90
-0.11 (-2.20%)
Sep 25, 2023, 10:14 AM EDT - Market open
-2.2%
Market Cap 51.91M
Revenue (ttm) 9.03M
Net Income (ttm) -18.04M
Shares Out 10.20M
EPS (ttm) -2.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,620
Open 4.96
Previous Close 5.01
Day's Range 4.90 - 5.17
52-Week Range 2.31 - 9.60
Beta 2.80
Analysts Buy
Price Target 5.05 (+3.06%)
Earnings Date Nov 9, 2023

About AWH

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endoc... [Read more]

Sector Healthcare
Founded 1993
Employees 85
Stock Exchange NASDAQ
Ticker Symbol AWH
Full Company Profile

Financial Performance

In 2022, AWH's revenue was $8.18 million, an increase of 20.14% compared to the previous year's $6.81 million. Losses were -$27.17 million, -14.19% less than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for AWH stock is "Buy." The 12-month stock price forecast is $5.05, which is an increase of 3.06% from the latest price.

Price Target
$5.05
(3.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aspira Women's Health Signs Exclusive Sample Procurement Agreement with The University of Oxford

Samples to be used in validating the Company's EndoCheck SM test in development for the diagnosis of endometriosis

25 days ago - GlobeNewsWire

Aspira Women's Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations

AUSTIN, Texas, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc.(“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women's health diagnostic t...

4 weeks ago - GlobeNewsWire

Aspira Women's Health® Reports Second Quarter 2023 Financial Results

Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022.

5 weeks ago - GlobeNewsWire

Aspira Women's Health Announces Transition of its Chief Scientific Officer/Chief Operating Officer

AUSTIN, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynec...

6 weeks ago - GlobeNewsWire

Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 14, 2023

AUSTIN, Texas, July 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools...

2 months ago - GlobeNewsWire

Aspira Women's Health Regained Compliance with Nasdaq's Minimum Bid Price Requirement

AUSTIN, Texas, June 02, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease di...

4 months ago - GlobeNewsWire

Aspira Women's Health Announces the Publication of Three Abstracts by the American Society of Clinical Oncology (ASCO) Supporting the Clinical Utility of OvaSuite(SM) Ovarian Cancer Risk Assessment Tests

AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...

4 months ago - GlobeNewsWire

Aspira Women's Health to Participate at William Blair's 43rd Annual Growth Stock Conference

AUSTIN, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease di...

4 months ago - GlobeNewsWire

Aspira Women's Health to Present at the 2023 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Conference

AUSTIN, Texas, May 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...

4 months ago - GlobeNewsWire

Aspira Women's Health Names Torsten Hombeck as Chief Financial Officer

AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...

4 months ago - GlobeNewsWire

Aspira Women's Health to Host Investor Day on OvaWatch(SM) and EndoCheck™ Market Opportunities on May 23, 2023

AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...

4 months ago - GlobeNewsWire

Aspira Women's Health® Reports First Quarter 2023 Financial Results

First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year First Quarter cash used in operat...

4 months ago - GlobeNewsWire

Aspira Women's Health Announces 1-for-15 Reverse Stock Split

AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...

4 months ago - GlobeNewsWire

Aspira Women's Health Appoints Three New Members to its Board of Directors

AUSTIN, Texas, May 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease dia...

4 months ago - GlobeNewsWire

Aspira Women's Health Announces Preliminary First Quarter 2023 OvaSuite Volume Increase of 29% and Plans to Announce Full Earnings Results on May 11, 2023

Preliminary first quarter 2023 volume was 6,259 tests, an increase of 29% compared to last year, the highest volume quarter in the company's history

5 months ago - GlobeNewsWire

Aspira Women's Health Reports Fourth Quarter and Full Year 2022 Financial Results

2022 total revenue of $8.2 million, an increase of 20% year-over-year

6 months ago - GlobeNewsWire

Aspira Women's Health to Announce Year End 2022 Financial Results and Host Conference Call on March 22, 2023

AUSTIN, Texas, March 03, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (Nasdaq: AWH), a bio-analytical based women's health company focused on gynecologic disease, today announced that the compa...

7 months ago - GlobeNewsWire

Aspira Women's Health Announces National Payer Coverage for OvaWatch

First National Payer to Cover OvaWatch First National Payer to Cover OvaWatch

7 months ago - GlobeNewsWire

Aspira Women's Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights

Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021

9 months ago - GlobeNewsWire

Aspira Women's Health Announces Publication of Real-World Data Validating Use of OvaWatch for the Management of Adnexal Masses

Provides clinical validation for the use of OvaWatch SM in the assessment of ovarian cancer risk for suspected benign or indeterminate adnexal masses

9 months ago - GlobeNewsWire

Aspira Women's Health Announces Three Reimbursement Milestones that Improve Patient Access to its OvaSuite SM Testing Portfolio

Expanded Medicare coverage for multi-marker testing, including Ova1Plus® and OvaWatch SM , through the 2023 Omnibus Spending Bill

9 months ago - GlobeNewsWire

Aspira Women's Health Announces the Commercial Launch of OvaWatch(SM)

AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”), a bio-analytical based women's health company focused on gynecologic disease, announced the commercial launch of...

10 months ago - GlobeNewsWire

Aspira Women's Health Reports Third Quarter 2022 Financial Results

Increased year-over-year product revenue by 26% to $2.0 million and year-over-year product volume by 29% to 5,524 units

11 months ago - GlobeNewsWire

Aspira Women's Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022

AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that management will present and be available ...

1 year ago - GlobeNewsWire

Aspira Women's Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detection of Cancer in Filipino Women

Data demonstrates the accuracy of Aspira's multivariate assessment test OVERA in a non-White population and concludes use of OVERA to be better than CA-125 in detecting early-stage cancer in women wit...

1 year ago - GlobeNewsWire